JERSEY, Channel Islands, July 01, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that the Company has been added to the Russell 2000® and 3000® Indexes

Scientists carrying out coronavirus antibody testing in Scotland are telling Clyde News we still don't have answers on the big question about immunity.

The Honeyman Group, a longstanding Quotient partner, today announced the launch of a new, highly sensitive antibody test utilizing the high-throughput MosaiQ™ platform which coupled with PCR screening can provide a systematic approach for businesses managing teams back-to-work”.

Corona Antikörpertests rücken immer mehr in den Vordergrund. Gross in diesem Geschäft ist der Basler Pharma-Multi Roche. Neu auf dem Markt behauptet sich das Waadtländer Start-up Quotient.

On the 8th of June, reporter Gordon Chree from STV visited Quotient's Allan-Robb Campus in Penicuik, Scotland to interview Quotient Chief Operating Officer. While on site, he was also tested using the MosaiQ COVID-19 Antibody Microarray. 

On the 6th of June 2020, The Sun journalist Alex Bellotti visited an hVIVO laboratory in East London to try out the newly launched “gold standard” coronavirus antibody test provided by Quotient using their MosaiQ technology.

Quotient Das Startup bringt den ersten in der Schweiz  produzierten Antikörpertest  auf den Markt. Dahinter steckt ein Ex-Roche-Manager.

JERSEY, Channel Islands, May 11, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ

Quotient CEO Franz Walt was interviewed on 05 May 2020 by Mike Graham on talkRADIO. They discussed the recently CE marked MosaiQ COVID-19 Antibody microarray, antibody testing, and the global COVID-19 pandemic. 

JERSEY, Channel Islands, 1 May, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In V